0000000000303637

AUTHOR

Günter Auerswald

showing 2 related works from this author

A systematic overview of the first pasteurised VWF/FVIII medicinal product, Haemate P/Humate -P: history and clinical performance

2008

Patients with von Willebrand disease (VWD) and haemophilia A (HA) lack, to varying degrees, the von Willebrand factor (VWF) and coagulation factor VIII (FVIII) that are critical for normal haemostasis. These conditions in turn make patients prone to uncontrolled bleeding. Historically, patients with severe forms of VWD or HA were crippled before adulthood and their life expectancy was significantly reduced. Over the past decades, specific coagulation factor replacement therapies including Haemate P, have been developed to help patients achieve and maintain normal haemostasis. Haemate P is a human, plasma-derived VWF/FVIII medicinal product, which was first licensed in Germany in 1981 for th…

congenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyHaemophilia AHemophilia AHaemophiliaHaemate P; Humate-P; von Willebrand disease; von Willebrand factor; haemophilia; factor VIIIVon Willebrand factorhemic and lymphatic diseasesInternal medicinevon Willebrand FactormedicineVon Willebrand diseaseHumansDosingDesmopressinHematologybiologybusiness.industryHematologyGeneral Medicinemedicine.diseasevon Willebrand DiseasesCoagulationImmunologybiology.proteinSafetybusinessSettore MED/15 - Malattie del Sanguemedicine.drug
researchProduct

Recombinant, activated factor VII for surgery in factor VII deficiency: a prospective evaluation - the surgical STER

2010

Excessive bleeding represents a major complication of surgical interventions and its control is especially relevant in patients with Congenital Bleeding Disorders (CBD). In factor VII (FVII) deficiency, scanty data on surgery is available to guide treatment strategies. The STER (Seven Treatment Evaluation Registry) is a multi-centre, prospective, observational, web-based study protocol providing the frame for a structured and detailed data collection. Inhibitor occurrence was checked in a centralized fashion. Forty-one surgical operations (24 'major' and 17 'minor') were performed in 34 subjects with a carefully characterized FVII deficiency under the coverage of recombinant activated Facto…

Excessive Bleedingmedicine.medical_specialtyHematologyFactor VIIbusiness.industrymedicine.medical_treatmentHematologymedicine.diseaseSurgerychemistry.chemical_compoundDental extractionchemistryInternal medicineHemostasisOrthopedic surgerymedicineCoagulopathyProspective cohort studybusinessBritish Journal of Haematology
researchProduct